Anthony E. Peters

Anthony E. Peters

Auto-generated profile, based on publicly available information

Anthony E. Peters

Division of Cardiology, Duke University Hospital, Durham, NC; Duke Clinical Research Institute, Durham, NC

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
APAnthony E Peters
Anthony E Peters
JTJasper Tromp
Jasper Tromp
SSSanjiv J Shah
Sanjiv J Shah
CLCarolyn S P Lam
Carolyn S P Lam
GLGregory D Lewis
Gregory D Lewis
RMRobert J Mentz
Robert J Mentz
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity with complex pathophysiology and manifestations. Phenomapping is the process of applying statistical learning techniques to patient data to identify distinct subgroups based on patterns in the data. Phenomapping has emerged as a technique with potential to improve the understanding of different HFpEF phenotypes. Phenomapping efforts have been increasing in HFpEF over the past several years using a variety of data sources, clinical variables, and statistical techniques. This review summarizes methodologies and key takeaways from these studies, including consistent discriminating factors and conserved HFpEF phenotypes. We argue that phenomapping results to date have had limited implications for clinical care and clinical trials, given that the phenotypes, as currently described, are not reliably identified in each study population and may have significant overlap. We review the inherent limitations of aggregating and utilizing phenomapping results. Lastly, we discuss potential future directions, including using phenomapping to optimize the likelihood of clinical trial success or to drive discovery in mechanisms of the disease process of HFpEF.

14 February 2021 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
APAnthony E. Peters
Anthony E. Peters
APAmbarish Pandey
Ambarish Pandey
CAColby Ayers
Colby Ayers
KWKara Wegermann
Kara Wegermann
RMRobert W. McGarrah
Robert W. McGarrah
MFMarat Fudim
Marat Fudim
Aims Non‐alcoholic fatty liver disease leads to progressive liver fibrosis and appears to be a frequent co‐morbid disease in heart failure with preserved ejection fraction (HFpEF). It is well known that liver fibrosis severity predicts future liver‐related morbidity and mortality, but its impact on outcomes in patients with HFpEF remains unknown. This analysis aimed to describe the prevalence of liver fibrosis, as assessed using surrogate biomarkers, in patients with HFpEF and the association of such biomarkers in predicting clinical outcomes in these patients. Methods and results Patients with HFpEF from TOPCAT Americas were included in the analysis. The non‐alcoholic fatty liver disease fibrosis score (NFS) and fibrosis‐4 (FIB‐4) scores were calculated using a combination of clinical characteristics and laboratory parameters. Risk of advanced fibrosis was classified as low, intermediate, and high. For the 1423 with sufficient data, we used Cox regression analysis to test the association between the risk of fibrosis severity and the combined primary endpoint of all cardiovascular death, aborted cardiac arrest, and hospitalization for heart failure. Advanced fibrosis, as determined by high fibrosis scores, was present in 37.57% by the NFS and 8.02% by the FIB‐4. Higher risk of advanced hepatic fibrosis was associated with older age. In unadjusted models, the risk of advanced fibrosis was associated with the primary cardiovascular outcome [NFS high vs. low, hazard ratio (HR) 1.709 (95% confidence interval, CI 1.238–2.358, P = 0.0011) and FIB‐4 high vs. low, HR 1.561 (95% CI 1.139–2.140, P = 0.0056)]. After multivariable adjustment, this association was diminished [NFS high vs. low, HR 1.349 (95% CI 0.938–1.939, P = 0.1064) and FIB‐4 high vs. low, HR 1.415 (95% CI 0.995–2.010, P = 0.0531)]. Conclusions Our study suggests that advanced liver fibrosis, as estimated by fibrosis risk scores, may not be uncommon in patients with HFpEF, and there appears to be a limited independent association between liver fibrosis risk scores and clinical outcomes related to heart failure events.

1 August 2019 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
APAnthony E. Peters
Anthony E. Peters
LSLaVone A. Smith
LaVone A. Smith
PAPriscilla Ababio
Priscilla Ababio
KBKhadijah Breathett
Khadijah Breathett
TMTimothy L. McMurry
Timothy L. McMurry
SMSula Mazimba
Sula Mazimba

3 January 2022 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
APAnthony E. Peters
Anthony E. Peters
RMRJ Mentz
RJ Mentz
TDTracy A. DeWald
Tracy A. DeWald
SGStephen J. Greene
Stephen J. Greene
Torsemide is a loop diuretic that inhibits the Na+/K+/2Cl− cotransporter type 2 in the thick ascending loop of Henle, leading to increased excretion of urinary sodium and chloride and associated di...

9 September 2022 in The American Journal of Cardiology
Verified
Journal Article
Open access
APAnthony E. Peters
Anthony E. Peters
KCKaren Chiswell
Karen Chiswell
PHPaul Hofmann
Paul Hofmann
AAAndrew Ambrosy
Andrew Ambrosy
MFMarat Fudim
Marat Fudim
The role of digoxin in clinical practice has narrowed over time. Data on digoxin toxicity trends and outcomes are variable and lacking in granularity for treatment outcomes. This study aimed to address data gaps in digoxin toxicity trends and outcomes in patients treated with or without digoxin immune fab (DIF). This single-center analysis examined patients with signs/symptoms concerning for digoxin toxicity, defined as hospital admission or emergency department visit with elevated digoxin serum concentrations (>2 ng/mL) and/or primary diagnosis code of digoxin toxicity and/or DIF order. Between 2000–2020, 727 patients were identified with signs concerning for digoxin toxicity with mortality rates of 12.7% during admission and 42.7% at 1 year. DIF was ordered in 9% of cases. Incidence of digoxin toxicity per 1000 patients with a digoxin prescription and frequency of DIF treatment fluctuated over time without a clear trend toward increase or reduction. DIF-treated patients demonstrated a heavier co-morbidity burden and lower presenting heart rates (median 53 [39.5–69.5] vs 77 [64.0–91.5] bpm, p<0.001), worse renal function (median estimated glomerular filtration rate, 30.3 [14.8–48.6] vs 40.0 [24.2–61.2] mL/min/1.73 m2, p=0.013), and higher potassium (median 4.5 [4.0–5.3] vs 4.3 [3.9–4.8] mEq/L, p=0.022). Compared with a matched cohort, DIF-treated patients experienced non-significant, numerically lower in-hospital mortality (8.2% vs 15.8%, p=0.199) and 30-day all-cause hospitalization (14.3% vs 24.7%, p=0.112) and similar 6-month and 1-year hospitalization and mortality. In conclusion, digoxin toxicity remains a pertinent public health issue despite reduction in digoxin utilization. DIF therapy is utilized in a medically complex population with high-acuity illness at presentation and is associated with non-significant trends toward reduced in-hospital mortality and early readmission that are attenuated over time.

7 September 2022 in JACC: Heart Failure
Verified
Journal Article
Closed access
APAnthony E. Peters
Anthony E. Peters
DKDalane W. Kitzman
Dalane W. Kitzman
HCHaiying Chen
Haiying Chen
MNM. Benjamin Nelson
M. Benjamin Nelson
APAmy M. Pastva
Amy M. Pastva
RMRJ Mentz
RJ Mentz